Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
相关临床试验
15
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
13.3%
已完成
10
66.7%
招募中
1
6.7%
终止
1
6.7%
撤回
1
6.7%
暂无批准数据
- The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs developing 110+ oncolytic virus drugs. - Key market drivers include growing cancer incidence in hard-to-treat solid tumors, increasing understanding of cancer biology, advancements in viral engineering, and rising adoption of personalized medicine approaches. - Leading companies such as Candel Therapeutics, Oncolytics Biotech, and CG Oncology are advancing promising therapies like CAN-2409, Pelareorep, and CG0070 through Phase III clinical trials. - Recent developments include innovative combination approaches, with Imugene and JW Therapeutics collaborating on CF33-CD19 with CAR-T therapy, and multiple FDA designations granted including Fast Track and RMAT status.
- Pelareorep combined with standard-of-care therapy achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable colorectal cancer, compared to 6-11% with standard therapy alone. - The investigational immunotherapy more than doubled both progression-free survival and overall survival compared to bevacizumab plus FOLFIRI treatment regimen. - Translational analysis revealed pelareorep enhanced KRAS-mutant-specific T-cell populations, providing mechanistic support for its precision immunotherapy approach. - Oncolytics Biotech plans to advance pelareorep into a controlled study following regulatory consultation to validate these promising signals in this difficult-to-treat patient population.
- Researchers at Augusta University discovered that combining beta-blockers with oncolytic herpes simplex virus significantly improves breast cancer treatment by blocking tumor's protective mechanisms and reprogramming immune cells. - Scientists at The Institute of Cancer Research demonstrated that pairing reovirus with targeted drugs talazoparib and palbociclib dramatically boosts immune responses and cancer cell death in laboratory and mouse studies. - Both studies reveal how tumors manipulate the body's stress responses and immune systems to resist treatment, offering new strategies for more effective personalized cancer therapies. - The combination approaches not only enhance immediate tumor destruction but also help train the immune system to develop memory against cancer recurrence.
- Oncolytics Biotech announced voluntary delisting from the Toronto Stock Exchange effective August 22, 2025, while maintaining its Nasdaq listing under symbol "ONCY." - The clinical-stage immunotherapy company cited cost-benefit analysis and U.S. focus as key reasons, with plans to cease Foreign Private Issuer status by January 1, 2026. - The company continues developing pelareorep, an immunotherapeutic agent with Fast Track designation from FDA for metastatic pancreatic and breast cancers. - Canadian shareholders can continue trading through U.S.-registered broker-dealer affiliates, and the company remains a reporting issuer in Canadian provinces.
- The BRACELET-1 trial demonstrated that pelareorep combined with paclitaxel achieved a 31% objective response rate and 12.1-month median progression-free survival in HR+ HER2- metastatic breast cancer patients. - Patients receiving the paclitaxel-pelareorep combination showed enhanced T-cell proliferation by cycle 4, suggesting improved immune activation compared to paclitaxel alone. - Adding avelumab to the combination paradoxically reduced efficacy and increased toxicity, with the triple regimen showing only 14% response rate and 5.8-month median PFS. - The findings support further investigation of pelareorep as an immunotherapy option for HR+ HER2- breast cancer, a subtype historically resistant to immune-based treatments.
- Oncolytics Biotech has appointed Jared Kelly as CEO, leveraging his expertise from orchestrating the $2 billion sale of Ambrx Biopharma to Johnson & Johnson. - The company's lead immunotherapy pelareorep has achieved FDA Fast Track designation for metastatic pancreatic and breast cancers, with >60% objective response rates in pancreatic cancer trials. - Pelareorep demonstrated survival benefits 4-6 times higher than historical controls in pancreatic cancer and meaningful survival improvements in over 100 metastatic breast cancer patients. - The appointment aims to accelerate pelareorep's development toward registrational studies and potential strategic partnerships in the immunotherapy space.
- The oncolytic virus cancer therapy market is experiencing robust growth with over 120 companies actively developing 125+ pipeline therapies, representing a significant expansion in this therapeutic segment. - The global market for oncolytic virus immunotherapy was valued at $156.8 million in 2024 and is projected to reach $429.1 million by 2030, growing at a CAGR of 18.3%. - Several promising candidates are advancing through late-stage clinical trials, including Olvi-Vec in Phase III for platinum-resistant ovarian cancer and CG0070 in Phase III for non-muscle invasive bladder cancer. - Recent breakthroughs in synthetic biology and vector engineering are enhancing the safety, selectivity, and immune-stimulatory capabilities of oncolytic viruses through genetic modifications and combination protocols.
- Oncolytics Biotech will present new data from Cohort 1 of the GOBLET study at the 2025 ASCO Annual Meeting in Chicago. - The data will demonstrate pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. - PDAC is characterized by poor prognosis and limited treatment options, representing a significant unmet medical need. - Following the announcement, Oncolytics shares declined $0.02 to $0.76 on the Toronto Stock Exchange.
- The Paul-Ehrlich-Institute (PEI) in Germany has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. - Cohort 5 is evaluating pelareorep in combination with mFOLFIRINOX with or without atezolizumab in newly diagnosed PDAC patients. - Early safety data will be presented at the upcoming ASCO Gastrointestinal Cancers Symposium, with initial efficacy results expected in the second half of the year.
- Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers. - A GOBLET study cohort showed a 33% objective response rate in relapsed anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months. - Bio-Path Holdings reported a meaningful patient response in a Phase 1/1b trial of BP1002 for refractory/relapsed AML, with stable disease and reduced blast count after one treatment cycle. - Bio-Path Holdings' BP1001-A demonstrated continued tumor reduction and stable disease in a solid tumor patient, alongside durable remissions in AML patients treated with prexigebersen.
